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Serum levels of mature microRNAs in DICER1-mutated
pleuropulmonary blastoma
MJ Murray1,2,7, S Bailey1,7, KL Raby2, HK Saini3, L de Kock4, GAA Burke1, WD Foulkes4, AJ Enright3, N Coleman2,5,8 and M Tischkowitz6,8
DICER1 is a critical gene in the biogenesis of mature microRNAs, short non-coding RNAs that derive from either -3p or -5p precursor
microRNA strands. Germline mutations of DICER1 are associated with a range of human malignancies, including pleuropulmonary
blastoma (PPB). Additional somatic ‘hotspot’ mutations in the microRNA processing ribonuclease IIIb (RNase IIIb) domain of DICER1
are reported in cancer, and which affect microRNA biogenesis, resulting in a -3p mature microRNA strand bias. Here, in a germline
(exon11 c.1806_1810insATTGA) DICER1-mutated PPB, we ﬁrst conﬁrmed the presence of an additional somatic RNase IIIb hotspot
mutation (exon25 c.5425G4A [p.G1809R]) by conventional sequencing. Second, we investigated serum levels of mature microRNAs
at the time of PPB diagnosis, and compared the ﬁndings with serum results from a comprehensive range of pediatric cancer
patients and controls (n¼ 52). We identiﬁed a panel of 45 microRNAs that were present at elevated levels in the serum at the time
of PPB diagnosis, with a signiﬁcant majority noted be derived from the -3p strand (P¼ 0.013). In addition, we identiﬁed a subset of
10 serum microRNAs (namely miR-125a-3p, miR-125b-2-3p, miR-380-5p, miR-125b-1-3p, let-7f-2-3p, let-7a-3p, let-7b-3p, miR-708-3p,
miR-138-1-3p and miR-532-3p) that were most abundant in the PPB case. Serum levels of two representative microRNAs,
miR-125a-3p and miR-125b-2-3p, were not elevated in DICER1 germline-mutated relatives. In the PPB case, serum levels of
miR-125a-3p and miR-125b-2-3p increased before chemotherapy, and then showed an early reduction following treatment. These
microRNAs may offer future utility as serum biomarkers for screening patients with known germline DICER1 mutations for early
detection of PPB, and for potential disease-monitoring in cases with conﬁrmed PPB.
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INTRODUCTION
DICER1 is a member of the ribonuclease III (RNase III) family and is
critically involved in the biogenesis of microRNAs, short non-
protein-coding RNAs that negatively regulate protein-coding gene
expression, as well as other functions that include chromatin
regulation and alternative splicing.1 DICER1 is a 1922-amino-acid
protein that contains, among other important domains, two RNase
III domains (IIIa and IIIb) toward the C terminus, responsible for the
processing of microRNA precursor molecules. DICER1 mutations
may be germline or somatic in nature. Germline mutations occur
throughout the gene, although the functional consequences are
variable.2 Although the protein from the affected allele is
predicted to be truncated or not produced at all, owing to
nonsense-mediated decay, some DICER1 protein may still be
produced.2 In contrast, somatic ‘hotspot’ mutations generally
occur in the RNase IIIb domain.1,3 In humans, heterozygous
germline mutations of DICER1 are associated with several
childhood cancers, such as the rare lung tumor pleuro-
pulmonary blastoma (PPB),4 Wilms tumor, cystic nephroma and
other conditions such as multinodular goiter.5 Recently, biallelic
DICER1 mutations have been demonstrated to account for a small
proportion of Wilms tumor.1
PPBs are composed of malignant mesenchymal cells, often
associated with benign epithelium.4 The majority of children with
PPB are found to have germline DICER1 mutations, although
penetrance of these mutations is low.6 Relatively little is known
about the potential mechanisms through which mutations in
the DICER1 gene may lead to tumor development. However,
most data are consistent with a standard two-hit model of
tumorigenesis, where the ﬁrst germline mutation is followed at a
later stage by a second somatic mutation, almost exclusively in the
RNase IIIb domain, in certain cell types (e.g. those of the lung or
thyroid) that subsequently manifest as organ-speciﬁc disease (e.g.
PPB or goiter). Immunohistochemical analysis for DICER1 protein
expression in various tumors from patients known to harbor
germline DICER1 mutations has yielded inconsistent results for
both biological and technical reasons.4,5 In PPB cases, for example,
expression from the wild-type DICER1 allele has been shown to be
lost in tumor epithelium, but is retained in the malignant
mesenchymal cells,4 and differences in the sensitivity and
speciﬁcity of individual DICER1 antibodies remain to be fully
characterized.5
The RNase III domains of the DICER1 protein process precursor
stem-loop microRNAs (pre-microRNAs) in the cytoplasm to
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produce single-stranded, mature microRNAs (18–23 nucleotides
(nt) in length). Mature microRNAs arising from the 50 end of the
stem-loop precursor are termed -5p microRNAs, and those from
the 30 end as -3p microRNAs. These are incorporated into the RNA-
induced silencing complex, where they regulate gene expression
through binding to messenger RNA targets.7 DICER1 mutations of
the RNase IIIb domain are associated with altered microRNA
processing, in particular a strand bias toward the production of
-3p rather than -5p microRNAs, owing to the loss of -5p strand
cleavage of the pre-microRNA.3
Importantly, microRNA proﬁles have been shown to classify
human cancers.8 For example, we have shown that microRNA
proﬁles universally segregate malignant germ cell tumors (GCTs)
from non-malignant controls9 and that the same microRNAs
are detectable at high levels in the serum of patients at the
time of malignant GCT diagnosis,10–12 ﬁndings recently replicated
by others.13,14 These diagnostic serum microRNA proﬁles are
sensitive enough to detect malignant GCT disease at tumor
volumes as low as 4 cm3.11
Here, we studied a 2-year-old girl at the time of PPB diagnosis,
who was found to harbor a germline DICER1 mutation. She initially
presented with a 1-week history of cough and fever. Family history
was suggestive of a germline DICER1 mutation (Figure 1a). Chest
computed tomography (CT) scan conﬁrmed a large left-sided
chest mass (Figure 1b). Lytic metastatic deposits were noted in the
thoracic spine and ribs. Biopsy conﬁrmed a ‘Type III’ PPB (http://
www.ppbregistry.org/) (Figure 1c). Mutation analysis of DNA from
lymphocytes identiﬁed a heterozygous germline DICER1 insertion
mutation, c.1806_1810insATTGA (Figure 1d, top panel), resulting
in a frameshift and therefore presumed to be deleterious
(Figure 1e, top panel). The same mutation was subsequently
identiﬁed in the patient’s mother and maternal grandmother, in
keeping with the family history. Staging investigations conﬁrmed
further metastatic bony deposits, including in the occipital region.
Figure 1. Clinicopathological data for the DICER1-mutated PPB case. (a) Family tree showing the history consistent with a germline DICER1
mutation on the maternal side (þ / ¼heterozygous for the germline mutation). (b) Chest CT scan at presentation revealed a large left-sided
chest mass, causing displacement of the heart and compression of the left lung. (c) Representative hematoxylin and eosin stain showing the
Type III PPB, taken at  20 magnification using a Nikon Eclipse TS100 microscope and a Nikon DS-Fi1 camera (Nikon UK Ltd, Kingston upon
Thames, UK). (d) Electrophoretogram showing the germline heterozygous c.1806_1810insATTGA DICER1 mutation (upper panel) and the
somatic c.5425 G4A [p.G1809R] DICER1 RNase IIIb domain mutation (lower panel). Tumor DNA was extracted and DICER1 RNase IIIa and RNase
IIIb domains screened for ‘hotspot’ mutations, as described.1 Polymerase chain reaction (PCR) amplification of the regions of interest was
performed as described24 and sequencing undertaken by the McGill University and Genome Quebec Innovation Center (MUGQIC) using
conventional Sanger sequencing methods. (e) Schematic of the DICER1 protein showing site of the germline-truncating mutation (upper
image) and somatic RNase IIIb domain mutation (lower image). (f ) Magnetic resonance imaging brain scan showing the right-sided cerebral
metastasis and the left occipital bony metastatic deposit.
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Chemotherapy was commenced according to the PPB Registry
treatment recommendations (http://www.ppbregistry.org/) and 12
courses were delivered over 9 months with objective radiological
response. However, reassessment at the end of treatment,
including magnetic resonance imaging of the head, revealed a
new right-sided cerebral metastasis (Figure 1f). She received
palliative whole brain radiotherapy, but presented acutely 10 days
later with left-sided weakness. A computed tomography head
scan conﬁrmed an increase in size of the right-sided cerebral
metastasis. She received palliative support and died 1 year after
initial presentation.
For this study, we ﬁrstly screened tumor tissue for the presence
of an additional somatic mutation of the RNase IIIa and RNase IIIb
domains. We then quantiﬁed global levels of mature microRNAs in
the serum at the time of diagnosis of PPB, comparing ﬁndings
with serum results from pediatric cancer patients and controls
(n¼ 52). We compared results with those from the proband’s
mother and maternal grandmother who both carried the same
germline DICER1 mutation and demonstrated that PPB-speciﬁc
serum microRNAs showed an early response to treatment. We
have identiﬁed microRNAs that may offer future utility as serum
biomarkers for screening patients with known germline DICER1
mutations for early detection of PPB, and for potential disease
monitoring in cases with conﬁrmed PPB.
RESULTS AND DISCUSSION
Analysis of the DICER1 RNase IIIa and RNase IIIb domains in tumor
tissue conﬁrmed a somatic ‘hotspot’ mutation within exon 25,
resulting in a c.5425G4A [p.G1809R] mutation affecting the RNase
IIIb domain (Figure 1d, bottom panel). This mutation has been
observed previously in a PPB case (Foulkes et al., unpublished) and
is predicted to result in replacement of a glycine with arginine at
position 1809 of the 1922-amino-acid DICER1 protein. This
mutation is predicted to reduce RNase IIIb activity, likely to result
in abnormal processing of microRNA precursor molecules in
affected tissues (Figure 1e, bottom panel). This ﬁnding is consistent
with the demonstration that somatic RNase IIIb hotspot mutations
of DICER1 occur in association with germline mutations, particularly
loss-of-function mutations.3 Mutant DICER1 proteins resulting from
somatic mutations generally have reduced RNase IIIb activity but
retain RNase IIIa activity,15 and are associated with defective
microRNA processing and -3p strand bias.3 It is believed that such
mutations in epithelial lung tissue result in the subsequent
development of PPB in pulmonary mesenchymal cells,4 although
the precise mechanisms remain to be characterized.
Following global microRNA proﬁling of the diagnostic serum
sample from the DICER1-mutated PPB case, the normalized Ct data
showed that there were similar levels of serum mature microRNAs
(n¼ 568) to other tumors of childhood and to control samples
(Figure 2a). Of the 568 expressed microRNAs, a total of 286 had
both -3p and -5p probes present on the Exiqon platform, for
which there was a very similar expression level of both strands in
all 53 samples analyzed (Figure 2b). This ﬁnding suggested that a
germline mutation per se was not sufﬁcient to cause a general
reduction in mature microRNA levels in the bloodstream. In body
tissues only affected by a single germline DICER1 mutation, the
second DICER1 allele appears to permit enough functional DICER1
protein to be produced to maintain mature microRNA levels,
reﬂected by similar abundances in the serum.
These ﬁndings are consistent with the notion that the major
contributions to overall serum levels of mature microRNAs
within the body in patients with PPB are from tissues that only
harbor a single germline mutation, with no evidence of microRNA
strand bias.
We next hypothesized that the large PPB tumor (Figure 1b)
would release speciﬁc microRNAs into the bloodstream, which
would be detectable as an altered serum proﬁle compared with
control serum samples and with diagnostic serum samples from
the time of diagnosis of other childhood tumors. In total, we
identiﬁed a list of 45 mature microRNAs that were overexpressed,
that is, were at levels X2.0-fold higher in the serum at DICER1-
mutated PPB diagnosis, compared with both the cohort of ‘other
tumors’ of childhood and the control group (Supplementary
Table S1). Given the direct evidence of a somatic DICER1 RNase IIIb
mutation in this PPB case, and the known association with
defective microRNA processing,3 we next looked for evidence of a
-3p strand bias in the overexpressed microRNAs in the serum from
the DICER1-mutated PPB case. Of the original list of 45
overexpressed microRNAs, 14 had no speciﬁc -3p or -5p strand
information and a further microRNA (miR-1237-3p) had no
corresponding -5p probe on the test platform (Supplementary
Table S1). The remaining 30 microRNAs had both -3p and -5p
probes represented on the platform, of which 21 were derived
from the -3p strand and only nine from the -5p strand (P¼ 0.013;
exact binomial test) (Supplementary Table S1).
Table 1 lists the 10 microRNAs (from the original list of 45) that
were the most abundant in the PPB case compared with all the
other 52 samples analyzed. Of these, nine were from the -3p
strand and only one from the -5p strand (P¼ 0.0098). These data
indicate the robust presence of a -3p strand bias among
overexpressed PPB-associated serum microRNAs. Levels of these
10 microRNAs were between 3.4- and 40-fold higher in the serum
of the PPB patient when compared with mean serum levels in the
control group (Table 1). The most substantial increase was for miR-
125a-3p, with levels over 40- and 33-fold higher than the control
group and the ‘other tumor’ group, respectively. We next
interrogated whether the 10 serum microRNAs that were elevated
at PPB diagnosis have also been reported in other pulmonary
malignancies. Of note, 8 of the 10 microRNAs showed altered
expression in non-small-cell lung cancer (NSCLC) in adults, either
in tumor tissue or patient serum at diagnosis (Table 1).16–21 The six
top-ranking microRNAs from our subset of 10 (miR-125a-3p, miR-
125b-2-3p, miR-380-5p, miR-125b-1-3p, let-7f-2-3p and let-7a-3p)
are represented graphically in Figure 2c.
To determine whether serum levels of representative micro-
RNAs were PPB-speciﬁc or indicative only of changes due to
germline DICER1 mutations, we compared the ﬁndings for the two
highest ranking differentially expressed microRNAs (miR-125a-3p
and miR-125b-2-3p) with levels from two family members (mother
and maternal grandmother) known to harbor the same germline
DICER1 mutation that was detected in the patient (Figure 2d).
Although serum levels of miR-125a-3p and miR-125b-2-3p were
similarly low in the mother and grandmother, levels were 41- and
17-fold higher, respectively, in the PPB case at diagnosis (day (d)
 11 before treatment commenced), compared with levels in the
mother, conﬁrming their speciﬁcity for PPB (Figure 2d). These
changes were similar to the fold changes seen for these
microRNAs in the PPB case compared with the pediatric control
samples (Table 1).
We next analyzed serum levels of miR-125a-3p and miR-125b-2-
3p at the four time-points from which serum was available in the
PPB case, representing two time-points before the delivery of
chemotherapy (i.e. during diagnostic work-up), and two following.
We observed that the levels of these two representative
microRNAs increased during diagnostic work-up and brieﬂy
‘ﬂared’ on commencement of chemotherapy (Figure 2d) (as we
have observed for serum microRNAs in other tumor types (data not
shown)), before rapidly falling at d þ 12 to levels below those seen
at baseline assessment (d  11). Finally, using linear regression, we
showed that levels of miR-125a-3p and miR-125b-2-3p were highly
correlated (P¼ 0.0002) (Figure 2d, right panel), suggesting that
changes in the levels of these two independently transcribed
microRNAs (Table 1) were disease-associated.
Of the lung malignancy-associated microRNAs, high tissue
expression levels of miR-708 are strongly associated with an
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Figure 2. Serum mature microRNAs in the DICER1-mutated PPB case. (a) The graph shows global mean Ct values for serum mature microRNAs
(n¼ 568) in the PPB case at the time of diagnosis (red; left) compared with mean values for the reference tumors of childhood (without a
family history suggestive of germline DICER1 mutations) (n¼ 32; blue; center) and age- and gender-matched control samples from subjects
without malignancy (n¼ 20; green; right). Serum samples were processed10 before RNA extraction (miRNeasy Mini Kit; Qiagen, Crawley, UK), as
described.25 The RNA eluate was used for universal reverse transcription using miRCURY-LNA microRNA reagents (Exiqon, Vedbaek, Denmark).
The universal cDNA was diluted 50 , before quantitative reverse transcription polymerase chain reaction (qRT–PCR) for 741 human
microRNAs using the Exiqon microRNA Ready-to-Use PCR Human-Panels I and II in a LightCycler 480 Real-Time-PCR System (Roche, Welwyn
Garden City, UK), including spike-in controls for quality control. MicroRNAs with Ct values p37 were considered expressed. Samples had no
evidence of significant hemolysis, by visual inspection and analysis of miR-451 levels, as described.26 Data were normalized using the global
mean method, that is, the average Ct value of microRNAs expressed in at least one of the 53 samples analyzed (n¼ 568), as described.27
MicroRNA levels were then quantified using the delta Ct method. MicroRNAs that had a X2.0 fold change in expression in the PPB case
compared with the mean expression value from a) the control group and b) the ‘other tumor’ group were considered overexpressed. (b) The
graph shows the expression of -3p (top panel) and -5p (lower panel) microRNAs as a percentage of the total number of expressed microRNAs.
The PPB case at the time of diagnosis (red column) is compared with percentages for individual ‘other tumor’ samples (blue) and controls
(green). Only expressed microRNAs with both -3p and -5p probes present on the Exiqon qRT–PCR platform (n¼ 286) were considered for this
analysis. (c) Levels of the six top-ranking most abundant microRNAs (from Table 1) for the DICER1-mutated PPB sample (red) when compared
with other childhood tumor samples (blue) and controls (green). (d) The graphs show separate validation of the normalized serum levels of
miR-125a-3p (left) and miR-125b-2-3p (center) and linear regression of these two microRNAs (right) in four longitudinal serum samples from
the PPB case (red) and from serum from relatives with the same germline DICER1 mutation (mother and maternal grandmother; gray). For this
work, the non-human spike-in microRNA cel-miR-39-3p was used for quality control, before levels were normalized using three independently
transcribed housekeeping microRNAs that were identified in the global study as having the most stable expression in the serum across the
whole cohort (miR-191-5p, miR-30b-5p and miR-30c-5p). This independent qRT–PCR was performed using Taqman reagents and assays
(Applied Biosystems, Warrington, UK) as per the manufacturer’s instructions using a Realplex Mastercycler epgradient S (Eppendorf,
Stevenage, UK). Results were then referenced to serum microRNA levels from the mother. Time-points listed are relative to the start of
chemotherapy treatment, assigned as d 0. d, Day; M, mother; GM, maternal grandmother.
Serum microRNAs in pleuropulmonary blastoma
MJ Murray et al
4
Oncogenesis (2014), 1 – 6 & 2014 Macmillan Publishers Limited
increased risk of death from NSCLC after adjustments for all
clinically signiﬁcant risk factors, including patient age, gender and
tumor stage.16 MicroRNAs including miR-125a17 and members of
the let-7 family18,19 have been shown to be signiﬁcantly
downregulated in NSCLC tumor samples, with low levels of
expression associated with poor clinical outcomes. The
observation that levels of these microRNAs may be
downregulated in lung malignancy (compared with normal lung
tissue), but detected at elevated levels in the serum (as shown
here for PPB), is consistent with other ﬁndings. For example, miR-
206, a muscle-speciﬁc microRNA, is downregulated in
rhabdomyosarcoma samples (compared with normal skeletal
muscle) and associated with poor overall survival,22 but found at
elevated levels in the serum when compared with normal
controls.23 Derangement of normal cellular function, allowing
passive leakage of such microRNAs from tumor cells into the
bloodstream, may be one explanation for these observations.
Alternatively, active and selective microRNA release mechanisms
from tumor cells could account for the described ﬁndings, which
may in turn promote an environment suitable for tumor cell
growth and metastasis. To this end, miR-125b has been shown to
be highly expressed in the serum of patients with NSCLC, with
levels correlating with tumor stage,21 whereas miR-138 has been
associated with the development of cisplatin resistance in
NSCLC.20 The PPB-associated serum microRNAs identiﬁed here
are therefore likely to reﬂect both an origin from malignant lung
tissue and a contribution from biallelic DICER1 mutations, resulting
in microRNA processing changes and a -3p strand bias. It will be
important in the future to study serum microRNA proﬁles in other
non-pulmonary DICER1-mutated tumors, to quantify such relative
contributions more precisely.
We acknowledge the potential limitations of our study. We did
not interrogate for microRNA proﬁles in the PPB tissue, owing to a
lack of normal lung parenchyma samples for suitable comparison.
First, however, as microRNAs that are detected at altered levels in
the serum10–12 are often dysregulated in malignant tissues,9 serum
proﬁling may be used directly to identify candidate biomarkers.
Second, it will be important in the future to conﬁrm these serum
ﬁndings in a larger cohort of PPB cases, as we have done for
malignant GCTs,10–12 as, to the best of our knowledge, we are not
aware that any such PPB serum sample set currently exists. Finally,
it is possible that a very small minority of tumor cases in our
comparison group may have been from patients carrying
undetected germline DICER1 mutations, as we only performed
gene sequencing in the PPB case. However, it should be noted
that the family history obtained in the non-PPB tumor cases was
not suggestive of such mutations and that germline PPB
mutations are rare, even in individuals with DICER1-associated
non-PPB tumors such as Wilms tumor and rhabdomyosarcoma.
If conﬁrmed in future studies, we propose that the panel of PPB-
associated microRNAs identiﬁed here may represent useful
screening biomarkers for PPB in patients known to have germline
DICER1 mutations and those with a suggestive family history. If so,
this approach may reduce or obviate the need for regular
surveillance imaging, with the associated risks of radiation
exposure (for computed tomography scans) and/or general
anesthesia and sedation (required to perform magnetic resonance
imaging scans in young children). In conﬁrmed PPB cases, it will
be important to identify whether levels of these serum microRNAs
accurately reﬂect disease activity and may therefore offer
potential for disease monitoring. Further functional studies are
also required to identify fully how DICER1 mutations result in the
development of PPB.
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Table 1. The most abundant serum mature microRNAs in DICER1-mutated PPB
MicroRNA and
miRBase accession
number
50–30 nucleotide sequence Chromosomal
location(s)
PPB
fold
change
‘Other tumor’
fold change
Implication in NSCLC Publication
miR-125a-3p
(MIMAT0004602)
ACAGGUGAGGUUCUUGGGAGCC 19q13.41 40.28 1.19 Tissue levels correlate with
stage and metastases
Jiang et al.17
miR-125b-2-3p
(MIMAT0004603)
UCACAAGUCAGGCUCUUGGGAC 21q21.1 14.84 0.71 High serum levels correlate
with poor prognosis
Yuxia et al.21
miR-380-5p
(MIMAT0000734)
UGGUUGACCAUAGAACAUGCGC 14q32.31 9.26 0.30 N/A N/A
miR-125b-1-3p
(MIMAT0004592)
ACGGGUUAGGCUCUUGGGAGCU 11q24.1 6.41 0.66 High serum levels correlate
with poor prognosis
Yuxia et al.21
let-7f-2-3p
(MIMAT0004487)
CUAUACAGUCUACUGUCUUUCC Xp11.22 5.92 0.96 Tissue levels correlate with
reduced survival
Takamizawa
et al.19
let-7a-3p
(MIMAT0004481)
CUAUACAAUCUACUGUCUUUC 9q22.32;
22q13.31
5.87 1.11 Tissue levels correlate with
shortened survival
Takamizawa
et al.19
let-7b-3p
(MIMAT0004482)
CUAUACAACCUACUGCCUUCCC 22q13.31 4.57 1.23 Tissue levels correlate with
worse survival
Jusofovic
et al.18
miR-708-3p
(MIMAT0004927)
CAACUAGACUGUGAGCUUCUAG 11q14.1 4.15 0.78 Tissue levels correlate with
increased risk of death
Jang et al.16
miR-138-1-3p
(MIMAT0004607)
GCUACUUCACAACACCAGGGCC 3p21.32 3.95 0.56 Role in cisplatin resistance Wang et al.20
miR-532-3p
(MIMAT0004780)
CCUCCCACACCCAAGGCUUGCA Xp11.23 3.43 1.58 N/A N/A
Abbreviations: N/A, not available; NSCLC, non-small-cell lung cancer; PPB, pleuropulmonary blastoma. The table lists the 10 microRNAs that were most
abundant in the serum in the DICER1-mutated PPB case at the time of diagnosis compared with the control group and the other childhood tumors (‘other
tumors’) group. It also provides information on sequence, chromosomal location and fold change in the PPB case and ‘other tumor’ samples referenced to the
normal control samples. Further information is provided for the microRNAs that have been implicated in adult lung malignancy.
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